DCGI allows Serum Institute for Vaccine trial on kids aged 7-11 years

Vaccine trial on kids aged 7-11 years

87
DCGI CDSCO

Last Updated on September 29, 2021 by The Health Master

BENGALURU -India’s drug regulator Drugs Controller General India (DCGI) on Tuesday allowed vaccine maker Serum Institute to enroll kids aged 7-11 years for its C-19 vaccine trial as the country prepares to protect children from the C-19 virus.

It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.

“After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol,” a subject expert panel of the Central Drugs Standard Control Organization (CDSCO) said.

Serum Institute is already conducting a trial of its C-19 vaccine, a domestically produced version of U.S. drugmaker Novavax’s shot, in the 12-17 age group and has presented safety data for an initial 100 participants.

So far, only drugmaker Zydus Cadilas DNA C-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.

Covishield

Covaxin

Sputnik V

Modenra

NPPA fixes retail price of 23 formulations: September 2021

DCGI’s nod to AstraZeneca to import, market Selumetinib Capsules

New 3D Printed Vaccine Patch offers greater protection than jabs

PCI publishes Syllabus for Diploma in Pharmacy Course 2021-22

Medical Devices registration will benefit industry: DCGI

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner